Menu di pagina
- IRE Research and Technology
- IRE Competitive Grants
- PerfeTTO
- INNOVA
- Immune Metabolism Dysregulation and Efficacy of Anti-PD-1/PD-L1 Agents in Non-Small Cell Lung Cancer (NSCLC)
- Artificial Intelligence and Machine Learning Based Risk Prediction Model for Improving Endometrial Cancer Clinical Management
- Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation after robot-assisted surgical treatment of genitourinary cancers
- Deciphering KEAPness for Improved Immunotherapy Prediction and Treatment
- MiRNA-based therapeutic approach to fight triple negative breast cancer
- Beyond the creation of a living biobank: dissecting the transcriptomic landscape of Gastro-entero-pancreatic neuroendocrine neoplasms
- Multidimensional assessment of virus-associated head and neck cancer patients for the discovery of predictive biomarkers to guide clinical intervention
- TArgeting drug resistant melanoma with miCroRNAs delivered by Lipid NanoparTICles (TACTIC)
- Addressing liver fibrosis prevention and treatment: an unbiased query on the hepatic microenvironment with a perspective targeting of the pro-fibrotic kinase HIPK2
- Analyses of HPV and host body fluid biomarkers as non-invasive strategy for detection of head and neck cancer relapse
- Deciphering Biology of R/R DLBCL Subtypes: miRNA Biomarkers for Optimizing Treatment and Survival
- Clinically approved drugs targeting pyruvate kinase M2: a drug repurposing pathway to move forward the treatment of glioblastoma
- Developing a Biobank Network Among Major Sarcoma Treatment Centers to Improve Biomedical Research
- Identification and Validation of Prognostic and Predictive Biomarkers, Including E3 Ubiquitin Ligases and MicroRNA Signature, for the Development of New Immunotherapeutic Approaches in Glioma
- Heal Italia
- D3 4 Health
- TRIglIFO2 project
- Poc MIMIT Project
- The PROMlSE project
- The 4Immunogenomics project
- Project ERBB2
- Project NANO-COVID-TEST
- Progetto DOMINO – Lazio Innova
- Project GEMMA – Lazio Innova
- Project COMETA
- Exploring the role of Bcl-2 family in the immune surveillance of melanoma: from mechanisms to therapeutic perspectives
- Exploring how endothelin-1/PIEZO axis intersects mechanical forces to fuel PARP inhibitor resistance in ovarian cancer
Project ERBB2
The IFO - IRCCS Regina Elena National Cancer Institute, is the coordinator of the project "Noninvasive proteogenomics in breast cancer: a liquid biopsy assay for two-dimensional nanophotonic determination of gene amplification and overexpression of the protooncogene ERBB2".
Project description
The application and industrial value of the method is to offer a tool not yet available on the market today, which is easy-to-use, within the reach of any hospital that is equipped with an integrated clinical pathology laboratory, for two-dimensional evaluation of ERBB2 and potentially applicable to other tumor markers as well. This forward-looking tool, anticipates the likely evolution of precision oncology in the near future. It is now a fact that: oncology moves on the basis of clinical evidence (much less on the basis of biological evidence) toward an increasing use of therapies based on anti-ERBB2 monoclonal antibodies.
Purpose
The application and industrial value of the method is to offer a tool not yet available on the market today, which is easy-to-use, within the reach of any hospital that is equipped with an integrated clinical pathology laboratory, for two-dimensional evaluation of ERBB2 and potentially applicable to other tumor markers as well. This forward-looking tool, anticipates the likely evolution of precision oncology in the near future. It is now a fact that: oncology moves on the basis of clinical evidence (much less on the basis of biological evidence) toward an increasing use of therapies based on anti-ERBB2 monoclonal antibodies.
Results
Our multidisciplinary research group brings together physicians (Regina Elena) and bio-engineers (Sapienza). Our challenge is practically to demonstrate that using ERBB2-2D 'in the field' can improve the standard of care for our patients by identifying mechanisms of resistance to treatment, and the right time to change therapy, all in a non-invasive manner. The nanophotonic methodology employed (light as a detector of the presence of ERBB2) will save us the effort and money, but more importantly lends itself to a full integration into an increasingly 'connected' digital and integrated National Health Care System, compared to internationally accepted standards (FISH and IHC) on tissue.
Financial Support
The total cost of the grant-eligible project, on the expenditure of which Lazio Innova has granted a maximum grant funding of 100 percent, is €149,999.85.
The funding resources are from the Public Notice "Research Groups 2020 POR FESR LAZIO 2014-2020" Determination G08487 of 19/07/2020 (BURL N.93 of 23/07/2020 - amended by Determination No. G10624/2020 - BURL No. 116 of 22/09/2020), Prot. Application No. A0375-2020- 36630; CUP: H85F21000250009, approved by Determination No. G04014 of 13/04/2021 published in BURL No. 38 of 15/04/2021, CUP: H85F21000250009.
The European Regional Development Fund (ERDF) aims to consolidate economic and social cohesion in the European Union by correcting any disparities that may exist between regions.